Board of directors

Frank Lison

Chairman of the board
Frank Lison has 25 years of experience in the photonics industry. He received his PhD in Applied Physics from Bonn University, Germany. After starting his industrial career at Bayer AG, focusing on the development of tools for high throughput screening, Frank served as VP of Research & Development at TOPTICA Photonics. With two other investors he bought microscope manufacturer TILL Photonics from Agilent, turned it around and sold it to FEI Inc, then continued to work for FEI as Senior Director overseeing the business segment of cell biology.
Since leaving FEI, Frank is working as an independent consultant and serves his clients as board member, advisor, facilitator, or trainer in go to market strategies, technology, and product development.

 

Celia Hart

Board member
Celia Hart has more than 20 years’ experience in the chemical and biotechnology sectors. Before joining CEA Investissement in 2005, she was head of lead optimization at Cambridge Antibody Technology (UK) and marketing and commercial manager (ESRF, France).
She is currently investment director at CEA Investissement in charge of life sciences. Celia has a degree in chemistry (Geneva, CH), a PhD in chemistry (Oxford, UK) and an MBA (Grenoble EM, France).

 

François Thomas

Board member
Dr. François Thomas is general manager and managing partner of Inserm Transfert Initiative (ITI). He is a medical oncologist and a former assistant professor at the Gustave Roussy Institute. He also holds an MBA from MIT (Boston). François Thomas was successively vice president (VP) for clinical development of Ipsen, managing partner of Bioserve Ltd, VP in charge of pharmacogenomic programs and licensing at Genset, partner in the venture capital firm Atlas Venture, in charge of healthcare banking activities at Bryan Garnier, and president of Cytheris. His professional activity over the last 15 years has been dedicated to the creation and development of biotech companies in Europe.

 

Jérôme Feraud

Board Observer
Jérôme FERAUD degree holder in immunology, and of a diploma of the ITB, is Investment Manager of Viveris Management. He began his career in the finance within the Credit du Nord, after one year as a freelance web developer.He joigned the Audit and Valuation team of Viveris Management in 2006 before moving to the Capital Venture division in 2007.
Jerome FERAUD succeeded into performing investments in the Healthcare sector and was a Board member of most of these companies. He was notably administrator as well as censor during the initial public offerings of Ipsogen and Adocia.
Since leaving FEI, Frank is working as an independent consultant and serves his clients as board member, advisor, facilitator, or trainer in go to market strategies, technology, and product development.

 

Pierre Rivaux

Board Member
Pierre Rivaux has a long track record of success in the medtech industry. After graduating from Skema business school (Lille, France) he became a serial entrepreneur; his 2nd company was acquired by Tyco Healthcare (now Medtronic), which he joined first as Managing Director France, then Vice President EMEA. He then joined Intuitive Surgical (DaVinci robot) as Vice President International, bringing revenue to 230m$ in 5 years.
Subsequently he joined Leica Microsystems (Danaher) as Vice President EMEA, driving significant growth in 3 divisions (Life Science Research, Surgical Microscopy and Industry), with a direct staff of 400 plus 250 distributors, in 134 countries. Pierre is also member of the Board of Axilum Robotics.
Since leaving FEI, Frank is working as an independent consultant and serves his clients as board member, advisor, facilitator, or trainer in go to market strategies, technology, and product development.

 

Gariel Sirat

Board Member

Gabriel Sirat is an expert in crystal optics. Prior to founding BioAxial, Gabriel spent 27 years at various positions in high tech companies including Optimet which he co-founded and where he served as CTO. Optimet is an optical metrology company which offers measurement solutions for several industrial and dental applications that were unmeasurable before. Optimet’s holding company, Ophir Photonics was acquired by Newport in 2011.
Dr. Sirat received his PhD in Applied Physics from the Hebrew University of Jerusalem in Israel and completed a postdoc at Caltech. He is the author of more than 20 patents and patent applications in imaging solutions based on crystal optics.

 

Georges Tabary

Board Member

Georges Tabary has a track record of business growth and innovation in the life sciences industry, in medtech and In Vitro Diagnostic. During the past 4 years he was Vice President, Strategic Accounts with Mauna Kea Technologies. Prior to this he spent 7 years with Leica Microsystems, leading the company’s operating microscopy and histopathology businesses in Europe, and was CEO of Leica Microsystèmes SAS (France). Prior to Leica, he launched and successfully managed Intuitve Surgical in Europe, spear-heading the company’s shift towards urology. He also spent 9 years in Japan, in top management positions in medtech and for Air Liquide Asia.